TP53 and cancer: In contrast, the same protocol frequently detected NY-ESO-1-specific CD8+ T cells in NY-ESO-1-seropositive cancer patients in the same study cohort, indicating that natural immunogenicity to induce spontaneous CD8+ T cell responses may be different in p53 and NY-ESO-1 even in seropositive patients for these antigens.